Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database

V. Amodru, P. Petrossians, A. Colao, B. Delemer, L. Maione, SJCMM. Neggers, B. Decoudier, P. Kamenicky, F. Castinetti, V. Hana, R. Pivonello, D. Carvalho, T. Brue, A. Beckers, P. Chanson, T. Cuny

. 2020 ; 70 (1) : 134-142. [pub] 20200619

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020035

PURPOSE: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and IGF-1 levels are usually congruent, indicating either remission or active disease; however, a discrepancy between GH and IGF-1 may occur. We aimed to evaluate the outcome of diabetes mellitus (DM) and hypertension (HT) in acromegalic patients with congruent GH and/or IGF-1 levels vs. discordant biochemical parameters. METHODS: Retrospective analysis of the data of 3173 patients from the Liege Acromegaly Survey (LAS) allowed us to include 190 patients from 8 tertiary referral centers across Europe, treated by surgery, with available data concerning DM and HT both at diagnosis and at the last follow-up (LFU). We recorded the number of anti-HT and anti-DM drugs used at the first evaluation and at LFU for every patient. RESULTS: Ninety-nine patients belonged to the REM group (concordant parameters), 65 patients were considered as GHdis (high random GH/controlled IGF-1), and 26 patients were considered as IGF-1dis (high IGF-1/controlled random GH). At diagnosis, 72 patients (37.8%) had HT and 54 patients had DM (28.4%). There was no statistically significant difference in terms of the number of anti-HT and anti-DM drugs at diagnosis versus LFU (mean duration: 7.3 ± 4.5 years) between all three groups. CONCLUSION: The long-term outcome of DM and HT in acromegaly does not tend to be more severe in patients with biochemical discordance in comparison with patients considered as in remission on the basis of concordant biological parameters, suggesting that patients with biochemical discordance do not require a closer follow-up.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020035
003      
CZ-PrNML
005      
20210830101634.0
007      
ta
008      
210728s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12020-020-02387-1 $2 doi
035    __
$a (PubMed)32562181
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Amodru, V $u Aix Marseille Univ, APHM, INSERM, MMG, Service d'endocrinologie, Hôpital de la Conception, Marseille, France
245    10
$a Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database / $c V. Amodru, P. Petrossians, A. Colao, B. Delemer, L. Maione, SJCMM. Neggers, B. Decoudier, P. Kamenicky, F. Castinetti, V. Hana, R. Pivonello, D. Carvalho, T. Brue, A. Beckers, P. Chanson, T. Cuny
520    9_
$a PURPOSE: Acromegaly is a rare disease due to growth hormone (GH)-secreting pituitary adenoma. GH and IGF-1 levels are usually congruent, indicating either remission or active disease; however, a discrepancy between GH and IGF-1 may occur. We aimed to evaluate the outcome of diabetes mellitus (DM) and hypertension (HT) in acromegalic patients with congruent GH and/or IGF-1 levels vs. discordant biochemical parameters. METHODS: Retrospective analysis of the data of 3173 patients from the Liege Acromegaly Survey (LAS) allowed us to include 190 patients from 8 tertiary referral centers across Europe, treated by surgery, with available data concerning DM and HT both at diagnosis and at the last follow-up (LFU). We recorded the number of anti-HT and anti-DM drugs used at the first evaluation and at LFU for every patient. RESULTS: Ninety-nine patients belonged to the REM group (concordant parameters), 65 patients were considered as GHdis (high random GH/controlled IGF-1), and 26 patients were considered as IGF-1dis (high IGF-1/controlled random GH). At diagnosis, 72 patients (37.8%) had HT and 54 patients had DM (28.4%). There was no statistically significant difference in terms of the number of anti-HT and anti-DM drugs at diagnosis versus LFU (mean duration: 7.3 ± 4.5 years) between all three groups. CONCLUSION: The long-term outcome of DM and HT in acromegaly does not tend to be more severe in patients with biochemical discordance in comparison with patients considered as in remission on the basis of concordant biological parameters, suggesting that patients with biochemical discordance do not require a closer follow-up.
650    12
$a akromegalie $x komplikace $x epidemiologie $7 D000172
650    12
$a adenom $7 D000236
650    12
$a diabetes mellitus $x epidemiologie $7 D003920
650    12
$a lidský růstový hormon $7 D019382
650    _2
$a lidé $7 D006801
650    12
$a hypertenze $x komplikace $x epidemiologie $7 D006973
650    _2
$a insulinu podobný růstový faktor I $7 D007334
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a riziko $7 D012306
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Petrossians, P $u Department of Endocrinology, CHU de Liège, Université de Liege, Liège, Belgium
700    1_
$a Colao, A $u Dipartimento Di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, University "Federico II", Naples, Italy
700    1_
$a Delemer, B $u Service d'endocrinologie, CHU de Reims, Reims, France
700    1_
$a Maione, L $u Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
700    1_
$a Neggers, S J C M M $u Section of Endocrinology Department of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
700    1_
$a Decoudier, B $u Service d'endocrinologie, CHU de Reims, Reims, France
700    1_
$a Kamenicky, P $u Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
700    1_
$a Castinetti, F $u Aix Marseille Univ, APHM, INSERM, MMG, Service d'endocrinologie, Hôpital de la Conception, Marseille, France
700    1_
$a Hana, V $u Third Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pivonello, R $u Dipartimento Di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, University "Federico II", Naples, Italy
700    1_
$a Carvalho, D $u Department of Endocrinology Diabetes and Metabolism, Centro Hospitalar Universitário S. João, Faculty of Medicine, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal
700    1_
$a Brue, T $u Aix Marseille Univ, APHM, INSERM, MMG, Service d'endocrinologie, Hôpital de la Conception, Marseille, France
700    1_
$a Beckers, A $u Department of Endocrinology, CHU de Liège, Université de Liege, Liège, Belgium
700    1_
$a Chanson, P $u Service d'Endocrinologie et des Maladies de la Reproduction, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France
700    1_
$a Cuny, T $u Aix Marseille Univ, APHM, INSERM, MMG, Service d'endocrinologie, Hôpital de la Conception, Marseille, France. thomas.cuny@ap-hm.fr
773    0_
$w MED00180215 $t Endocrine $x 1559-0100 $g Roč. 70, č. 1 (2020), s. 134-142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32562181 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101634 $b ABA008
999    __
$a ok $b bmc $g 1690762 $s 1140481
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 70 $c 1 $d 134-142 $e 20200619 $i 1559-0100 $m Endocrine $n Endocrine $x MED00180215
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace